The Fort Worth Press - European watchdog partially approves new Alzheimer's drug

USD -
AED 3.672991
AFN 67.000252
ALL 92.450024
AMD 386.974854
ANG 1.802123
AOA 912.999737
ARS 1004.028701
AUD 1.550664
AWG 1.8025
AZN 1.691108
BAM 1.857325
BBD 2.01886
BDT 119.48491
BGN 1.852673
BHD 0.37685
BIF 2897.5
BMD 1
BND 1.345641
BOB 6.908832
BRL 5.7881
BSD 0.999886
BTN 84.392794
BWP 13.725155
BYN 3.272208
BYR 19600
BZD 2.01548
CAD 1.406181
CDF 2866.000223
CHF 0.891097
CLF 0.03535
CLP 975.409788
CNY 7.230298
CNH 7.255885
COP 4483
CRC 510.721544
CUC 1
CUP 26.5
CVE 104.898224
CZK 24.039499
DJF 177.720367
DKK 7.089925
DOP 60.450038
DZD 133.619438
EGP 49.651402
ERN 15
ETB 121.924977
EUR 0.950575
FJD 2.274992
FKP 0.789317
GBP 0.79008
GEL 2.724985
GGP 0.789317
GHS 16.050165
GIP 0.789317
GMD 71.000134
GNF 8630.999733
GTQ 7.721894
GYD 209.184836
HKD 7.781525
HNL 25.079657
HRK 7.133259
HTG 131.382772
HUF 386.447959
IDR 15958.35
ILS 3.742715
IMP 0.789317
INR 84.479796
IQD 1310.5
IRR 42104.999699
ISK 138.4698
JEP 0.789317
JMD 158.287592
JOD 0.709098
JPY 156.361045
KES 129.502089
KGS 86.3765
KHR 4051.000028
KMF 466.50319
KPW 899.999621
KRW 1407.51502
KWD 0.30742
KYD 0.833207
KZT 495.71708
LAK 21944.999736
LBP 89599.999991
LKR 292.121707
LRD 184.10406
LSL 18.19889
LTL 2.95274
LVL 0.60489
LYD 4.879731
MAD 9.972503
MDL 18.112322
MGA 4659.999992
MKD 58.237769
MMK 3247.960992
MNT 3397.999946
MOP 8.01546
MRU 39.965002
MUR 47.189959
MVR 15.460093
MWK 1735.000056
MXN 20.44638
MYR 4.481991
MZN 63.849926
NAD 18.19805
NGN 1679.960183
NIO 36.760158
NOK 11.163435
NPR 135.033904
NZD 1.710952
OMR 0.385021
PAB 0.999905
PEN 3.804499
PGK 3.94225
PHP 58.903501
PKR 278.101709
PLN 4.106796
PYG 7808.968491
QAR 3.64075
RON 4.728699
RSD 110.633973
RUB 99.63521
RWF 1368
SAR 3.756031
SBD 8.383384
SCR 14.744996
SDG 601.501853
SEK 11.00999
SGD 1.34649
SHP 0.789317
SLE 22.704736
SLL 20969.504736
SOS 571.497762
SRD 35.356496
STD 20697.981008
SVC 8.749122
SYP 2512.529858
SZL 18.2053
THB 35.012982
TJS 10.658475
TMT 3.5
TND 3.151972
TOP 2.342103
TRY 34.33943
TTD 6.789045
TWD 32.619503
TZS 2660.000286
UAH 41.219825
UGX 3669.445974
UYU 42.477826
UZS 12799.999732
VES 45.453079
VND 25400
VUV 118.722009
WST 2.791591
XAF 622.917458
XAG 0.032786
XAU 0.000389
XCD 2.70255
XDR 0.753255
XOF 620.493331
XPF 113.383085
YER 249.849892
ZAR 18.284165
ZMK 9001.203741
ZMW 27.421652
ZWL 321.999592
  • RBGPF

    -0.9400

    59.25

    -1.59%

  • CMSC

    -0.0600

    24.55

    -0.24%

  • RYCEF

    -0.3200

    6.79

    -4.71%

  • SCS

    -0.1000

    13.27

    -0.75%

  • CMSD

    -0.0050

    24.725

    -0.02%

  • NGG

    0.2500

    62.37

    +0.4%

  • GSK

    -0.7200

    34.39

    -2.09%

  • VOD

    -0.0700

    8.68

    -0.81%

  • RIO

    -0.1900

    60.43

    -0.31%

  • BCC

    -2.2000

    140.35

    -1.57%

  • RELX

    -0.1700

    45.95

    -0.37%

  • JRI

    -0.0300

    13.21

    -0.23%

  • BTI

    0.0700

    35.49

    +0.2%

  • BCE

    -0.3700

    26.84

    -1.38%

  • AZN

    -0.2500

    65.04

    -0.38%

  • BP

    0.4800

    29.05

    +1.65%

European watchdog partially approves new Alzheimer's drug
European watchdog partially approves new Alzheimer's drug / Photo: © AFP

European watchdog partially approves new Alzheimer's drug

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer's disease, reversing an earlier decision not to give it the green light.

Text size:

"After re-examining its initial opinion, the EMA... has recommended granting marketing authorisation to Leqembi (lecanemab) for treating mild cognitive impairment or mild dementia due to Alzheimer's disease," the European Medicines Agency said, adding treatment would only apply to a certain group of patients.

Leqembi, developed by US multinational Biogen and Japanese-based Eisai, is the brand name of an active substance called lecanemab that is used to treat adults with mild memory and cognitive problems resulting from the early stages of the common type of dementia.

The EMA in July rejected a marketing request, saying the side effects, including potential brain bleeding, outweighed the benefits.

The EMA now endorsed the treatment, but only for patients with a lower risk of potential brain bleeding -- those who had "only one copy or no copy of ApoE4", a type of gene know as an important risk factor for Alzheimer's.

Such patients are less likely to experience certain serious health problems than people with two copies of the gene, the Amsterdam-based EMA said.

The health problems in question, known as amyloid-related imaging abnormalities (ARIA), include fluid on the brain and brain bleeding.

"The benefits of Leqembi outweigh the risks in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease with one or no copy of ApoE4."

This was "provided that risk minimisation measures are in place to reduce the risk of severe and symptomatic ARIA and monitor its consequences in the long term," it stressed.

Bringing down the risks included providing Leqembi through a "controlled access programme to ensure that the medicine is only used in the recommended patient population" and through MRI scans before and during treatment.

The Amsterdam-based EMA's approval will now be sent to the European Commission for a final decision to roll it out on the continent.

Pricing and reimbursement will be left up to member states, the EMA said.

Lecanemab has been hailed by Alzheimer's researchers and charities for being the first approved treatment which tackles the early stages of the disease, rather than managing the symptoms.

It works by using antibodies which bind to and clear the proteins that normally build up in the brains of people with Alzheimer's, the most common type of dementia.

The treatment has been shown to decrease cognitive decline by a quarter in people in the early stages of the disease.

Britiain's medicines regulator approved lecanemab in August, making it the country's first such licensed treatment.

Leqembi, together with another Alzheimer's drug called Aduhelm, received approval from the US Food and Drug Administration early last year.

W.Lane--TFWP